Edition:
United States

TG Therapeutics Inc (TGTX.OQ)

TGTX.OQ on NASDAQ Stock Exchange Capital Market

13.90USD
21 May 2018
Change (% chg)

-- (--)
Prev Close
$13.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
281,525
52-wk High
$17.30
52-wk Low
$7.25

Chart for

About

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered... (more)

Overall

Beta: 1.14
Market Cap(Mil.): $1,091.21
Shares Outstanding(Mil.): 77.67
Dividend: --
Yield (%): --

Financials

  TGTX.OQ Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -1.98 -- --
ROI: -138.38 -8.07 12.63
ROE: -142.02 -10.87 14.50

BRIEF-TG Therapeutics Reports Qtrly Loss Per Share Of $0.59

* TG THERAPEUTICS, INC. PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 08 2018

BRIEF-TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies

* TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES

Jan 08 2018

Competitors

Earnings vs. Estimates